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Background: Normal myoepithelial cells (MECs) play an important tumour-suppressor role in the breast but display an
altered phenotype in ductal carcinoma in situ (DCIS), gaining tumour-promoter functions. Matrix metalloproteinase-8
(MMP-8) is expressed by normal MECs but is lost in DCIS. This study investigated the function of MMP-8 in MECs and
the impact of its loss in DCIS.
Methods: Primary normal and DCIS-associated MECs, and normal (N-1089) and DCIS-modified myoepithelial (β6-1089)
cell lines, were used to assess MMP-8 expression and function. β6-1089 lacking MMP-8 were transfected with MMP-8
WT and catalytically inactive MMP-8 EA, and MMP-8 in N-1089 MEC was knocked down with siRNA. The effect on
adhesion and migration to extracellular matrix (ECM), localisation of α6β4 integrin to hemidesmosomes (HD), TGF-β
signalling and gelatinase activity was measured. The effect of altering MEC MMP-8 expression on tumour cell invasion
was investigated in 2D and 3D organotypic models.
Results: Assessment of primary cells and MEC lines confirmed expression of MMP-8 in normal MEC and its loss in
DCIS-MEC. Over-expression of MMP-8 WT but not MMP-8 EA in β6-1089 cells increased adhesion to ECM proteins and
reduced migration. Conversely, knock-down of MMP-8 in N-1089 reduced adhesion and increased migration.
Expression of MMP-8 WT in β6-1089 led to greater localisation of α6β4 to HD and reduced retraction fibre formation,
this being reversed by MMP-8 knock-down in N-1089. Over-expression of MMP-8 WT reduced TGF-β signalling and
gelatinolytic activity. MMP-8 knock-down enhanced TGF-β signalling and gelatinolytic activity, which was reversed by
blocking MMP-9 by knock-down or an inhibitor. MMP-8 WT but not MMP-8 EA over-expression in β6-1089 reduced
breast cancer cell invasion in 2D and 3D invasion assays, while MMP-8 knock-down in N-1089 enhanced cancer cell
invasion. Staining of breast cancer cases for MMP-8 revealed a statistically significant loss of MMP-8 expression in DCIS
with invasion versus pure DCIS (p = 0.001).
Conclusions: These data indicate MMP-8 is a vital component of the myoepithelial tumour-suppressor function. It
restores MEC interaction with the matrix, opposes TGF-β signalling and MMP-9 proteolysis, which contributes to
inhibition of tumour cell invasion. Assessment of MMP-8 expression may help to determine risk of DCIS progression.
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Many invasive breast cancers (IBC) develop through a
pre-invasive stage known as ductal carcinoma in situ
(DCIS) where the proliferative neoplastic cells are retained
within the breast duct surrounded by an intact myoepithe-
lial cell (MEC) layer lying in contact with basement mem-
brane [1]. DCIS is a non-obligatory precursor of IBC; only
around half of untreated cases progress to IBC, when the
tumour cells breach the MEC-basement membrane bar-
rier [2, 3]. However, the molecular mechanisms under-
lying the transition of DCIS to IBC are poorly understood,
and identifying those cases that will progress and those
that will not remains a major challenge [4, 5].
Molecular profiling studies demonstrate that DCIS
tumour cells and their invasive counterparts share a
similar signature and DCIS is as genetically advanced as
established invasive disease [6, 7]. Therefore, in order to
understand the changes that trigger invasion, attention
has focused on the role of the microenvironment [8–11].
MECs are a unique component of the microenvironment
in the breast. In normal breast ducts, MECs adhere
tightly to the basement membrane using prominent
hemidesmosome (HD) formation [12]. They show a high
level of expression of anti-tumourigenic factors, such as pro-
teinase inhibitors and anti-angiogenic mediators, and in vitro
studies have demonstrated broad tumour-suppressor activ-
ities of normal primary MEC and MEC lines [13–15]. In
DCIS, the MECs become altered, showing changes in gene
expression, epigenetics and phenotype [13, 14, 16, 17],
though the functional significance of these changes has not
been established [9, 18–20].
A previous study has indicated that in normal
ducts MECs appear to be the main source of matrix
metalloproteinase-8 (MMP-8), which is a major colla-
genase that cleaves Collagen type- I (Col -I) [21].
Expression of MMP-8 appears to be lost in DCIS-
associated MECs [22]. MMPs are a large family of
endopeptidases, which have the ability to remodel
extracellular matrix (ECM) and are upregulated in
many cancers, such that the MMP family is conven-
tionally regarded as consisting of key enzymes that
contribute to the process of cancer cell invasion and
metastasis [3, 23–25]. However, the failure of broad
range MMP inhibitors in anticancer trials suggests an
incomplete understanding of the complex function of
this family; specifically when and how they act in
cancer [3, 23–25]. Moreover; regulatory interactions
(compensation or inhibition) between MMP family
members construct a complex web through which the ex-
pression and activity of MMPs are constantly controlled
[25, 26]. One particular example is MMP-9, which is im-
plicated in the acquisition of DCIS-associated phenotype
in MECs [27] at the same stage when MECs lose MMP-8
expression. Since it was first reported that MMP-8-/- miceexhibit increased incidence of skin tumours when chal-
lenged with chemical carcinogenesis, MMP-8 has been
demonstrated to exert a clear tumour-suppressor function
[22, 26, 28, 29]. There is a growing body of evidence accu-
mulating that MMP-8 has an anticancer role in breast
cancer, malignant melanoma and tongue squamous cell
carcinoma, [22, 26, 28, 30–32]. Interestingly, identification
of non-structural substrates of MMP-8 [28, 33–37], sug-
gests that the biological function of MMP-8 is much more
complicated than just Col-I degradation.
The biological significance of loss of MEC-derived
MMP-8 on MEC phenotype and MEC-breast cancer cell
crosstalk remains elusive, especially whether MMP-8
may contribute to the tumour-suppressor function of
MECs. In this study we employed 2D and 3D in vitro
models to recapitulate the DCIS tumour microenviron-
ment in order to investigate how MMP-8 is involved in
MEC-breast cancer cell communication, and whether
loss of MMP-8 contributes to loss of tumour-suppressor
activity and promotes progression to invasive disease.
Improving our understanding of the factors that contrib-
ute to transition of DCIS to invasion will aid in the fu-
ture development of predictive signatures to help stratify
patient management more appropriately, and avoid the




Breast tissue samples were obtained from surgical speci-
mens from patients undergoing breast surgery at Barts
Health NHS Trust London. The study was performed
following patient consent and approval from the local
research ethics committee (reference: 05/Q0403/199 and
09/H075/39). Seven were normal breast cases from
reduction mammoplasty, nine were cases of DCIS (high,
intermediate and low grade) and nine were cases of
DCIS with concomitant invasion.
Sections were dewaxed in xylene and antigen retrieved
in citrate buffer pH6; followed by incubation with
MMP-8 rabbit polyclonal antibody (Atlas, Cambridge,
MA, USA, HPA02122, 1:750). Sections subsequently
were incubated with goat anti-rabbit biotinylated F(ab’)2
for 30 min, developed using ABC reagent and superDAB
(Dako, Glostrup, Denmark) then counterstained with
hematoxylin [7].
Cell lines and cell culture
All breast cancer cell lines were obtained from American
Type Culture Collection (ATCC) and verified with STR
profiling (LGC Standards, Teddington, UK, tracking num-
ber 710081047). MCF-7 and MDA-MB-231 cells were cul-
tured in 10% fetal bovine serum (FBS, PAA Laboratories,
Pasching, Austria, A15-14) containing (complete) DMEM
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in complete Ham’s F12 (PAA Laboratories, E15-817) with
hydrocortisone (Sigma-Aldrich, St. Louis, MO, USA, HO
888, 1 μg/ml) and insulin (Sigma-Aldrich, I9278, 1 μg/ml).
Generation of myoepithelial cell lines
The h-TERT/SV40 LgT immortalised MEC line was a
gift from M. O’Hare and P. Jat, Institute of Neurology,
UCL, London. αvβ6 integrin over-expressing and control
(normal) MEC line was generated as previously de-
scribed [27], and termed β6-1089 and N-1089 respect-
ively. These cells were cultured in the presence of
hydrocortisone (1 μg/ml), epidermal growth factor (EGF,
Sigma-Aldrich, 9644, 10 ng/ml), insulin (1 μg/ml) and
puromycin (1 μg/ml, Sigma-Aldrich) in Ham’s F12.
Isolation of primary myoepithelial and luminal epithelial
populations from normal breast and DCIS tissue
Primary cell isolation protocol was adapted from Gomm
et al. [38]. In brief, reduction mammoplasty tissue or
DCIS tissue was digested overnight at 37 °C with 1 mg/ml
collagenase (Sigma-Aldrich, C2674) and hyaluronidase
(Sigma-Aldrich, H3506) on a roller-mixer. Following
washing and a sedimentation step the organoids were fur-
ther digested with trypsin/EDTA (PAA Laboratories, L11-
004) and DNase (Roche Diagnostics, Basel, Switzerland,
10104159001) then filtered through a 40-μm filter (Becton
Dickinson, Franklin Lakes, NJ, USA). Cells were incubated
in a 1:1 ratio sequentially with magnetic beads (Dynal
Biotech., Milwaukee, WI, USA) coated with common
acute lymphoblastic leukemia antigen (CALLA) anti-
body (AbD Serotech, Oxford, UK, MCA1556) to isolate
normal MECs or anti-β4 integrin antibody (EMD Millipore,
Billerica, MA, USA, mAB 1964) for DCIS myoepithelial
cells. This was followed by epithelial cell adhesion molecule
(EpCAM) antibody-coated epithelial-enriched magnetic
beads (Invitrogen, Carlsbad, CA, USA, 161.02) to isolate
luminal epithelial cells (LECs). Primary fibroblasts were
grown from the media produced by the sedimentation step.
The purity of these populations has been verified by stain-
ing for CK8, CK18, EMA for the luminal epithelial cells
and CK14, SMA, CD10, vimentin, p63 for the myoepithelial
cells, as described in previous publications [27, 38].
MMP-8 over-expression
The wild-type MMP-8 (WT) and inactive mutant MMP-
8 (EA) coding inserts cloned into pcDNA4 (EcoRI and
XhoI restriction sites, Invitrogen, K103002) have been
described previously [39]. Empty pcDNA4 vector was
used as a control.
β6-1089 cells were plated at a density 7 × 104 cells per
well onto 6-well plates 24 hours prior to transfection. β6-
1089 cells were transfected with 1 μg DNA per well with
Genejuice reagent (Novagen, Merck KGaA, Darmstadt,Germany, 70967) according to the manufacturer’s instruc-
tions for 5 hours at 37 °C. All functional experiments were
performed 24 hours after transfection. For generation of
conditioned media (CM), complete media was replaced
with serum-free media (SFM) and harvested after 24
hours, followed by centrifugation at 1200 rpm for 3 mi-
nutes to remove cell debris and storage at -80 °C.MMP-8 knock-down
N-1089 cells were seeded onto six-well plates at a dens-
ity 7 × 104 cells per well and incubated for 24 hours at
37 °C, after which media was replenished and N-1089
cells were transfected with 5nM pooled MMP-8 siRNA
(Thermo Fisher Scientific, Waltham, MA, USA, MU-
005969-00-0020) or Luciferase GL3 Duplex control
siRNA (siLUC, Thermo Fisher Scientific, D-001400-01-20)
[40] using interferin transfection reagent (Polyplus tranfec-
tion, Peqlab Biotechnologie GmbH, Erlangen, Germany,
409-01) according to the manufacturer’s instructions. All
functional assays were carried out 96 hours after transfec-
tion. To generate CM, cells were serum starved for 24
hours and media was harvested as described above.Reverse transcription and q-PCR
RNA was extracted with RNeasy kit (Qiagen, Hilden,
Germany, 74104) and reverse transcribed with Super-
script II (Invitrogen, 11064-014). One hundred nano-
grams of cDNA were used per reaction.
All primers made up at 100 mM stock concentration
and used at 0.4 mM final concentration. Reactions were
performed using Immomix Red Master Mix (Bioline,
London, UK, Bio 25-022) in a total reaction volume of
25 μl. For nested PCR, 2 μl PCR product was used as a
template for second-round PCR. The products were
separated on a 1% agarose (Invitrogen, 16500-500) gel
for 45 min at 100v and visualised under UV light (Auto-
Chemi System, UVP, Cambridge, UK).
Q-PCR was carried out using SYBR Green (Applied
Biosystems, Foster City, CA, USA, 4367659) chemistry.
One hundred nanograms of cDNA input was used per
reaction. Primers were used at 0.3 mM final concentra-
tion in 10 μl total PCR volume for one well of a 96-well
plate. Reactions were carried out on a Step One Plus in-
strument (Applied Biosystems).
Primer sequences - MMP-8 forward: 5′-GCCGAAG
AAACATGGACCAAC-3′, MMP-8 nested forward: 5′-
ACTCCTCTGACCCTGGTGCC-3′, MMP-8 reverse:
5′- TGAGGATGCCTTCTCCAGAAG-3′, αvβ6 forward:
5′- GAAGGAATGATCACGTACAAG-3′, αvβ6 reverse:
5′- AGCAGGGAGTCTTCACAGGT-3′, 18 s forward:
5′-CACGGGAAACCTCACCCGGC-3′, 18 s reverse: 5′-
AGCAGGGAGTCTTCACAGGT-3′.
Sarper et al. Breast Cancer Research  (2017) 19:33 Page 4 of 19Western blotting
Cells were lysed with radioimmunoprecipitation (RIPA)
buffer. CM from N-1089 and β6-1089 cells was concen-
trated 20× using centrifugal units (EMD Millipore, 4FC
800324) with 3 K molecular weight cutoff (MWCO) at
4000 g for 45 minutes at 4 °C. Samples were boiled in
reducing (β-mercaptoethanol containing) laemmli buffer
for 5 minutes at 95 °C, then separated with SDS
(National Diagnostics, Atlanta, GA, USA, EC874) acryl-
amide (National Diagnostics, EC890) gel for 90 minutes
at 125 V at room temperature. Recombinant human
MMP-8 western blot standard (R&D Systems, Minneap-
olis, MN, USA, WBC017) was loaded as positive control.
The gel was transferred to a nitrocellulose membrane
(Hybon C extra, RPN203E) for 90 minutes at 30 V at
room temperature and Western blotting was performed
as previously described [27].
Primary antibodies used included mouse anti-human
MMP-8 antibody (R&D Systems, mAb 908), SMAD2
(Cell Signaling Technology, Danvers, MA, USA, 3122),
pSMAD2 (Cell Signaling Technology, 3101). Protein
loading was confirmed with HSC70 (Santa Cruz Biotech-
nology, Dallas, TX, USA, sc-7298) or actin (Santa Cruz
Biotechnology, sc-1615) as loading controls. For MMP-8
over-expressed samples, the membrane was probed with
anti-V5 antibody (Invitrogen, R960-25). Depending on the
primary antibody species, horseradish peroxidase (HRP)-
conjugated mouse secondary (Dako, P0447), rabbit sec-
ondary (Dako, P0448) or goat secondary (Dako; P0160)
antibody was used. The membrane was developed with
ECL (GE Healthcare, Chicago, IL, USA, RPN 2106) and
densitometric quantification analysis was performed with
Image J software (National Institutes of Health, Bethesda,
MD, USA).
Invasion assays
Boyden chamber transwells (Corning, Corning, NY,
USA, 3422, pore size: 8 μm) coated with 70 μl diluted
Matrigel (1 volume Matrigel: 2 volumes ice-cold serum-
free media) were used to measure in vitro invasive
capacity, as previously described [27]. 2 × 104 modified
β6-1089 or N-1089 cells were plated in serum-free
media in the lower chamber. 3 × 104 MCF-7, MDA-MB-
231or SUM159 breast cancer cells were seeded onto the
Matrigel-coated insert. Invasion assays were carried out
at 37 °C over 24 hours, or 48 hours for MCF-7 cells.
Invaded cells were harvested with 10× trypsin/EDTA
(PAA Laboratories, L11-003) from the underside of the
transwell and counted with a CASY counter (Schärfe
System, Reutlingen, Germany).
Viability assay
To analyse MEC viability, 3 × 104 β6-1089 or N-1089
cells were seeded onto a 24-well plate and incubated for24 hours at 37 °C after which the media was replenished
and MTS reagent (Promega, Madison, WI, USA, cell
titer 96 Aqueous, G5421) was added (5:1 media:MTS v/v
ratio) then incubated for 1 hour at 37 °C. The MTS con-
taining mixed media was then collected and placed on a
96-well plate and read at 495 nm (Tecan, Männedorf,
Switzerland, infiniteF50).
To analyse breast cancer cell viability 3 × 104 MCF-7,
MDA-MB-231 or SUM159 cells were incubated with
CM collected from modified β6-1089 or N-1089 cells for
24 hours. Viability was quantified using MTS reagent as
described above.
Adhesion assays
Non-tissue culture-treated 96-well plates were coated
with 100 μl of the following matrices in triplicate at
given concentrations: Fibronectin at 1 μg/ml, rat tail
Collagen-I (BD Biosciences, Franklin Lakes, NJ, USA,
354236) at 0.5 μg/ml, Matrigel at 0.5 μg/ml, Tenascin-C
(EMD Millipore, CC 065) at 3 μg/ml, Laminin-I at 10
μg/ml, Collagen-IV at 10 μg/ml and latency-associated
peptide (LAP) (Sigma-Aldrich, L3408) at 0.5 μg/ml.
Three wells of each plate were coated with 0.1% bovine
serum albumin (BSA, PAA Laboratories, K45-001) in
phosphate-buffered saline (PBS) (w/v) as a control.
Coated plates were incubated for 1 hour at 37 °C after
which wells were washed twice with 100 μl PBS per well.
Modified β6-1089 or N-1089 cells were serum starved
for 24 hours prior to the experiment. 3 × 103 cells were
seeded in 100 μl of serum-free Ham’s F12 per well and
allowed to adhere for 1 hour at 37 °C. Then 0.25 μl of
Calcein AM (Invitrogen, C1430) cell tracker was added
and incubated for 15 minutes at 37 °C after which the
plate was washed twice with 100 μl PBS per well, and
100 μl of SFM was added. The plate was read at 490/520
nm on a fluorescent reader (BMG Labtech, Aylesbury,
UK, FLUOstar Optima). The adhesion was calculated as
the fluorescence value of adherent cells and normalised
to that of control cells.
Migration assays
The underside of Boyden chamber transwells were
coated with 100 μl of ECM or 0.1% BSA in PBS as a
control, and incubated for 1 hour at room temperature.
ECM components and concentrations were as for the
adhesion assays. Following incubation the underside of
the transwell was washed with 100 μl PBS and placed
into 500 μl of SFM containing well of a 24-well plate.
3 × 104 modified β6-1089 or N-1089 cells were added
onto the inner chamber in 200 μl serum-free Ham’s F12
and incubated for 8 hours at 37 °C. After that the media
in the inner and outer chambers were replaced with 200
μl and 500 μl 10× trypsin EDTA respectively and incu-
bated for 1 hour at 37 °C. The cells were then trypsinised
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remaining in the inner chamber were counted using a
CASY counter. The percentage of migrated cells was cal-
culated using the counts of the upper chamber versus
total cell number.
Organotypic culture
Organotypic gels were constructed using rat tail
Collagen-I and Matrigel as previously described [27].
Briefly; for 10 gels, 4.9 ml rat tail Collagen-I was mixed
with 2.1 ml Matrigel (7:3 v/v ratio), 1 ml 10× DMEM
(Sigma-Aldrich, D2429) and 1 ml FBS. The pH of the
solution was neutralised by adding 1 M NaOH (Sigma-
Aldrich, S8045) drop-wise until the mixture turned an
orange-pink colour. 5 × 106 primary normal breast fibro-
blasts were suspended in 1 ml complete DMEM and
added to the neutralised gel mixture. One millilitre of
gel mixture was added to 1 well of a 24-well plate and
set for 1 hour at 37 °C. Following this, complete DMEM
was added drop-wise on top of the gels and equilibrated
overnight at 37 °C. The media was aspirated from the
top of the gels, 2.5 × 105 modified β6-1089 cells sus-
pended in 500 μl complete Ham’s F12 per gel were
added on top of the gels and incubated for 4 hours at 37
°C. Then 2.5 × 105 MDA-MB-231 or SUM159 cells in
500 μl complete DMEM per gel were added and incu-
bated overnight at 37 °C.
Collagen-I-coated nylon membranes (100-μm pore
size) were put on top of steel grids (coated side facing
up) in a well of a 6-well plate and the organotypic gels
placed on top. The well was filled with complete DMEM
until the liquid reached the grid-membrane interface
level; media was replenished every 2 days. The gels were
harvested after 10 days, fixed in 10% neutral-buffered
formalin (Cell Path, Newtown, UK, BAF-0010-037) over-
night and then transferred to 70% ethanol for 24 hours.
Gels were mounted in paraffin and sectioned.
Invadopodia assay (in situ zymography)
To analyse MEC-derived gelatinase activity an in situ
zymography assay was carried out. To prepare the gel-
atin solution, 178.12 mg NaCl (Thermo Fisher Scientific,
BB358-1), 94.57 mg NaBH4 (Sigma-Aldrich, 21,346-2)
and 100 mg porcine skin type A gelatin (Sigma-Aldrich,
G2500) were dissolved in 50 ml PBS for 1 hour at 37 °C
(pH 9.3), following which 1.8 mg rhodamine was added
to the solution and mixed for 2 hours to fluorescently
label the gelatin. The gelatin solution was dialysed
against PBS for 48 hours using Slide-A-Lyzer Dialysis
Cassettes with 10 K MWCO (Pierce, Rockford, IL, USA,
66830), the PBS being replenished every 24 hours. After
dialysis, the gelatin was collected and centrifuged at 1200
rpm for 10 minutes to remove insoluble particles, and
then 1 g sucrose (Thermo Fisher Scientific, 8060153) wasadded and dissolved. The rhodamine-conjugated gelatin
was spun at 1200prm for 10 minutes and then heated to
37 °C. Forty microlitres of solutions (drops) were ali-
quoted onto a 10-cm tissue culture plate. Thirteen-
millimetre coverslips were placed on each drop and incu-
bated for 20 minutes. All incubation steps were performed
in the dark. In another dish, 1% gluteraldehyde solution in
PBS (v/v) was aliquoted as 40 μl drops. After 20 minutes
gelatin-covered coverslips were placed on the gluteralde-
hyde solution to create a dual layer, and incubated for 15
minutes. The coverslips were placed in a 24-well plate
(dual-layered side facing up) and washed three times with
500 μl PBS, after which 500 μl 5 μg/ml NaBH4 was added
and incubated for 20 minutes then washed as described.
For sterilisation, coverslips were incubated with 500 μl
70% ethanol for 5 minutes, washed with PBS, then equili-
brated and free aldehydes quenched using 500 μl complete
Ham’s F12 for 20 minutes at 37 °C. Finally, 4 × 104 modi-
fied β6-1089 or N-1089 cells were added onto the cover-
slips and incubated for 24 hours.
After incubation, the cells were washed three times with
500 μl PBS and fixed in 4% formaldehyde (PFA, Sigma-
Aldrich, P6148) for 15 minutes at room temperature then
washed again as described. Cells were blocked in 0.1%
BSA (v/v) and 0.1% NaN3 (Thermo Fisher Scientific,
S227I) in DMEM (w/v) for 15 minutes in the dark at 4 °C,
then stained with FITC-labelled phalloidin (Invitrogen,
A22283) for 20 minutes in the dark at room
temperature. The coverslips were mounted in ProLong
Gold Antifade aqueous mounting reagent (Invitrogen,
P36931) with DAPI.
Immunoprecipitation of conditioned media
Two hundred microlitres of 20× concentrated CM
samples was cleared with 20 μl Protein A sepharose
beads (GE Healthcare, CL-4B) for 1 hour at 4 °C with
rotation. The samples were spun at 6000 rpm for 2
minutes at 4 °C and supernatant were collected. Pre-
cleared CM were divided into 100 μl aliquots and incu-
bated with 5 mg MMP-8 antibody (R&D Systems, mAb
908) or mouse IgG (Sigma-Aldrich, I5381) overnight at
4 °C with rotation.
Antibody treated CM was added to fresh 20 μl beads
and incubated for 4 hours at 4 ° C with rotation.
Samples were centrifuged as described. Supernatant
were collected and kept as unbound fraction. The
remaining pellet was washed with serum-free Ham’s F12
as described. In order to remove the precipitates from
the beads, 40 μl reducing Laemmli buffer was added to
20 μl cleared bead pellet and boiled at 100 °C for 10 mi-
nutes then spun once again. Supernatants were collected
and kept as bound fraction. Laemmli buffer was added
to unbound fraction and boiled at 100 °C for 5 minutes.
Twenty microlitres of prepared sample of bound or
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acrylamide gel and transferred to nitrocellulose as previ-
ously described, and probed with anti-MMP-8 or anti-
V5 antibody.
Immunofluorescence staining
Cells on coverslips were fixed with 4% PFA in PBS for
10 minutes at room temperature (RT). Cells were
washed three times with 500 μl PBS then blocked and
permeabilized with 2% BSA and 0.1% Triton X-100 in
PBS for 15 minutes. Finally, cells were incubated with
primary antibody prepared in blocking solution at 1/100
dilution for 1 hour at room temperature. Primary
antibodies used were α6β4 integrin (Merck Millipore,
Billerica, MA, USA, MAB1964) and plectin (Epitomics,
Burlingame, CA, USA, 1399). Cells were incubated with
secondary antibody conjugated with FITC or Cy3 diluted
in PBS. (Invitrogen, anti-mouse 546, A11030, anti-rabbit
546, A11035, anti-mouse 488, A11029, anti-rabbit 488,
A11008, phalloidin 546, A22283). The cells were mounted
in ProLong Gold Antifade aqueous mounting reagent with
DAPI. For organotypic cultures, Neso antibody was a kind
gift from Prof M. Djamgoz, Imperial College London.
For paraffin-embedded organotypic sections: sections
were dewaxed and rehydrated, then boiled in 10 mM
Tri-sodium citrate (pH 6) for 20 minutes. Sections were
then incubated in 0.5% Triton X-100 for 5 minutes at
RT. After that the sections were washed with PBS for 1
minute (three times) and blocked with 5% BSA/PBS for
1 hour at room temperature. Primary antibodies (p63;
Dako, M7247, 1/50, Neso; 1/300, Ki67; Novocastra,
Newcastle upon Tyne, UK, NCL-L-Ki67-MM1, 1/100)
were prepared in blocking solution and incubated for 1
hour at room temperature. After that sections were
washed with PBS for 5 minutes (three times). Fluores-
cently tagged secondary antibodies were prepared in
PBS and incubated for 45 minutes at RT. Finally, the
sections were washed as described followed by an extra
washing step with distilled water and mounted in Pro-
Long Gold Antifade reagent with DAPI. The Ki67 index
is calculated as the percentage of Ki67-positive invading
breast cancer cells out of the total cell number.
Luciferase reporter assay
MDA-MB-231 cells transfected with firefly and Renilla
luciferase reporter gene fused with PAI-promoter
(MDA-MB-231-Luc) were a gift from Dr Caroline Hill
(London Research Institute) and cultured in DMEM in
the presence of 50 μg/ml blasticidine (Sigma-Aldrich,
15205). MDA-MB-231- Luc cells were seeded onto 96-
well plates at a density of 4 × 104 cells per well and incu-
bated overnight at 37 °C, followed by serum starvation
for 4 hours. 5 × 104 modified β6-1089 or N-1089 cells
were seeded on top of MDA-MB-231-Luc cells in SFMand co-cultured overnight. The media was removed and
cells were washed with 100 μl PBS. Cell lysis and luciferase
activity quantification was performed using the Dual-
Luciferase Reporter Assay System (Promega, E-1910)
according to the manufacturer’s instructions.
Zymography
CM collected from modified β6-1089 or N-1089 cells
was concentrated as previously described and separated
by SDS-PAGE gel containing 3 mg Collagen-I for 50 mi-
nutes at 200 V. The gel was developed with developing
buffer [10 ml 1 M Tris (pH 7.5), 8 ml 5 M NaCl
(Thermo Fisher Scientific, BP358), 1 ml 1 M CaCl2
(Sigma-Aldrich, C7902), 1.6 ml 2.5%Triton X-100 and
179.4 ml sterile distilled water] overnight at 37 °C and
stained with Coomassie Blue R-250 solution (Thermo
Fisher Scientific, 20278).
Statistical analysis
Statistical significance was determined by Student’s t test
or ANOVA with Bonferroni post-test where appropriate,
using Prism (Graphpad Software, San Diego, CA, USA).
For immunohistochemical scoring of MMP8 on a duct-
by-duct basis Fisher’s exact test was used on a 2 × 3
table. Results were considered as significant with P value
less than 0.05.
Results
MMP-8 is expressed by normal myoepithelial cells and is
lost in DCIS-associated myoepithelial cells
In order to confirm previous observations that the pri-
mary source of MMP-8 in normal breast is the MEC
population and that it is lost in DCIS-associated MECs,
we first undertook to stain normal and DCIS tissue for
MMP-8. It can be seen in representative images in Fig. 1a
that normal MECs express MMP-8 while MECs associ-
ated with DCIS do not. Ducts from seven reduction
mammoplasty samples were homogenously positive for
MMP-8 (as was hyperplasia) (Additional file 1: Table
S1). Thirty-one of 68 (45%) ducts from nine cases of
pure DCIS (comprising high, intermediate and low
grade) were negative for MMP-8. Thirty-nine of 48
(81%) of ducts from nine cases of DCIS with invasion
were negative for MMP-8 (Additional file 2: Table S2).
These data indicate a progressive loss of myoepithelial
expression of MMP-8 from normal breast tissue to pure
DCIS to DCIS with invasion.
Subsequently, primary normal MECs, luminal epithelial
cells (LECs), fibroblasts and their DCIS-associated coun-
terparts were isolated from normal breast and pure DCIS
tissue respectively, as described [38], and a nested PCR for
MMP-8 was carried out. Normal breast MECs exhibit ex-
pression of MMP-8 whereas this expression is lost in
DCIS-associated MECs. MMP-8 expression was not
Fig. 1 MMP-8 expression in; primary normal and DCIS myoepithelial cells and a cell line model. a Normal and ductal carcinoma in situ (DCIS)
tissue immunohistochemically stained for matrix metalloproteinase-8 (MMP-8) (Atlas, HPA02122, 1:1000). Clear MMP-8 staining can be observed in
the normal myoepithelial cells (MECs), which is absent in the DCIS section. Magnification × 400. b Normal MECs and luminal epithelial cells (LECs)
were isolated from reduction mammoplasty tissue and DCIS MEC and DCIS LEC were isolated from a patient with high-grade DCIS. Tissues were
enzymatically digested and magnetic bead separation was used to isolated specific populations (MEC - ITGB4, LEC - EpCAM). RNA was extracted
from the isolated cells and G361 cells (a positive control for MMP-8), converted to cDNA by reverse transcription and then subjected to nested PCR for
MMP-8 or PCR of housekeeping gene 18S. The MMP-8 PCR produces a product of 150 bp in normal MEC and G361 lanes, and other lanes only give a
weak band. 18S gives a size of 52 bp in all sample lanes. The water (H2O) control lane shows no band. c (i) RNA was extracted from cell lines; G361, N-
1089 and β6-1089 and converted to cDNA as above. The cDNA was subjected to nested PCR for MMP-8 and bands were identified in G361 and N-
1089 but only a weak band was observed in the β6-1089 lane. All samples demonstrated a band for 18S. (ii) RIPA protein lysates were produced from
N-1089 and β6-1089 cells and 20 ug of protein was run on 8% PAGE then transferred to nitrocellulose and probed for MMP-8 (R&D Systems, mAb 908)
αvβ6 (Santa Cruz Biotechnology, SC-6632) or HSC70 as a loading control. The gel indicates that N-1089 expresses higher levels of MMP-8 and much
lower levels of αvβ6. While β6-1089 exhibit much higher levels of αvβ6 and lower levels of MMP-8. (iii) Densitometry of western blots indicates that
MMP-8 expression in N-1089 is 2.5-fold higher than N-1089 and (iv) αvβ6 expression in β6-1089 is 10-fold higher than N-1089
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tissue (Fig. 1b) or fibroblast populations (not shown). In
addition immunofluorescent dual labelling of the
myoepithelial-specific protein p63 and MMP-8 demon-
strates predominant myoepithelial localisation of MMP8
in a normal breast duct (Additional file 3: Figure S1).
One of the most consistent changes in DCIS-associated
MECs is upregulation of the integrin αvβ6 [41]. Therefore,
to establish a model for DCIS-associated MECs, a MECline over-expressing αvβ6 integrin (β6-1089) was gener-
ated from a normal, αvβ6-negative MEC line (N-1089), as
described [27]. To confirm that the β6-1089 line recapitu-
lates the in vivo phenotype of DCIS, RT Q-PCR for
MMP-8 was undertaken in both β6-1089 and N-1089 cell
lines. MMP-8 expression was downregulated in β6-1089
cells as compared to N-1089 cells at both the mRNA
(Fig. 1c i and iii) and protein level (Fig. 1c ii and iv), thus
reflecting the changes seen in human tissue.
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myoepithelial cells in a proteolytic-dependent manner
To analyse the gain-of-function effect of MMP-8 in our
model of DCIS-modified MEC, MMP-8 was re-introduced
into β6-1089 cells by plasmid over-expression (MMP-8
WT). To dissect the involvement of proteolytic activity of
MMP-8 in its biological role, cells were transfected with
an enzymatically inactive form of MMP-8 (MMP-8 EA),
generated by a point mutation in the catalytic domain in
which an essential glutamic acid residue is changed to ala-
nine [39]. In order to compare protein expression levels,
conditioned media (CM) were collected from cells trans-
fected with MMP-8 WT, MMP-8 EA or empty pcDNA4
vector, then concentrated 20×, and immunoprecipitated
for MMP-8. Unbound and immunoprecipitated (bound)
fractions were subjected to western blotting and similar
protein expression levels for WT and EA were observed,
with no detection in vector-only CM (Fig. 2a upper panel).
MMP-8 is a major collagenase that cleaves Collagen-I [21]
therefore the degradative activity of WTand EA forms was
examined using Collagen-I zymography. Degradation of
Collagen-I was observed only by CM from MMP-8 WT,
while MMP-8 EA or empty vector control failed to show
any degradation (Fig. 2a lower panel). This confirms the
inability of the EA form to cleave Collagen-I.
To analyse whether MMP-8 is involved in MEC ad-
hesion to ECM; MMP-8 WT, MMP-8 EA or control
cells were seeded onto different ECM and tracked
fluorescently by Calcein AM cell tracker. After 1
hour, non-adherent cells were washed and fluores-
cence generated from adherent MMP-8 WTand MMP-8
EA cells was normalised to empty vector. Over-expression
of MMP-8 WT significantly enhanced adhesion to Fibro-
nectin (Fib), Collagen-I (Col-I), Laminin-I (Lam-I or Lam
αI-βI-γI) and Tenascin-C (Ten-C) whereas there was a
significant decrease in adhesion to the N terminus
latency-associated peptide of transforming growth factor
beta (TGF-β) (LAP) (Fig. 2b i). LAP is an established
ligand for αvβ6 integrin whereby LAP cleavage by αvβ6
integrin leads to TGF-β activation [42]. In contrast,
MMP-8 EA cells, which lack proteolytic activity, showed
no evidence of increased ECM adhesion compared to
control cells.
To explore the effect of MMP-8 over-expression on
MEC migration towards ECM, transwell migration as-
says were performed. In this system MECs are sepa-
rated from ECM via a cell-permeable membrane and
cells move towards the ECM (Fig. 2b ii). Migration to-
wards Fib, Col-I, Lam-I, Ten-C and LAP was signifi-
cantly reduced in MMP-8 WT but not in MMP-8 EA
cells compared to control empty vector transfected
cells. The inability of MMP-8 EA to exert an effect on
adhesion or migration indicates that enzymatic activity
of MMP-8 is necessary for its function.To study the loss-of-function effect of endogenous
MMP-8 in our normal N-1089 cells, MMP-8 expression
was knocked down by siRNA transfection. Knock-down
of MMP-8 was confirmed at mRNA and protein level
(Fig. 2c i). Adhesion of MEC to Fib, Col-I, Col-IV, Lam-I
and Ten-C was significantly reduced in the absence of
MMP-8 (Fig. 2c ii) though interestingly there was no sig-
nificant difference in adhesion to the αvβ6 ligand LAP.
Transwell migration assays were used to analyse the
effect of lack of endogenous MMP-8 on directed migra-
tion. MMP-8 knock-down in N-1089 cells led to in-
creased migration towards Col-IV, Lam-I and Ten-C
while there was no significant alteration in migration to-
wards other ECM molecules (Fig. 2c iii).
MMP-8 WT modulates α6β4 integrin localisation
To further investigate the mechanism by which MMP-8
might influence MEC adhesion and migration, the ex-
pression and distribution of a major MEC integrin, α6β4
was examined by immunofluorescence. α6β4 integrin is
a key component of HDs, which are the adhesive struc-
tures responsible for stable attachment of the basal cell
surface of MEC to the basement membrane (Fig. 3a in-
sert). One unique alteration reported in DCIS MECs is
the disassociation of these structures [43, 44], α6β4 loca-
lising to invasion-associated actin complexes rather than
the adhesive plectin complex [45]. Confocal analysis of
dual-labelling for α6β4 and the HD component plectin
revealed that α6β4 localises more to HD structures in
MMP-8 WT compared to MMP-8 EA or control cells
(Fig. 3a i). Dual staining of α6β4 with phalloidin showed
that α6β4 also localises to actin-rich protrusion sites
(Fig. 3b i) and these retraction fibres were significantly
shorter and reduced in number in MMP-8 WT com-
pared to either EA or empty vector cells (Fig. 3b ii and
iii) consistent with the less migratory phenotype seen in
MMP-8 WT MECs. In addition, on Fibronectin matrix,
MMP-8 WT cells showed a greater degree of spreading
with a significant increase in occupied area (in pixels)
compared to MMP-8 EA or empty vector control cells
(Fig. 3b iv).
Immunofluorescence analysis of N-1089 cells following
MMP-8 knock-down revealed an increase in the length
and number of retraction fibres compared to control
knock-down cells, suggesting that MMP-8 inhibits the
formation of these fibres (Fig. 3c i, ii and iii).
Myoepithelial MMP-8 WT but not MMP-8 EA reduces
breast cancer cell invasion in 2D system via paracrine
interactions
Normal breast MECs previously have been shown to
reduce breast cancer cell invasion through paracrine
mechanisms [13]. Transwell invasion assays were used
to assess the involvement of MEC-derived MMP-8 in
Fig. 2 MMP-8 expression alters myoepithelial cell adhesion and migration to ECM proteins. a Upper panel: immunoprecipitation of matrix
metalloproteinase-8 (MMP-8) from 20× concentrated conditioned media of β6-1089 transiently transfected with wild-type MMP-8 (WT), inactive
point mutant of MMP-8 (EA) or empty vector (EMPTY). Conditioned media (CM) was incubated overnight with MMP-8 antibody (R& D Systems,
mAb 908) or IgG (Sigma-Aldrich) and bound proteins were precipitated with Protein A beads (B) and unbound supernatant was also collected
(UB). Samples were separated by 10% SDS-PAGE and probed with anti-V5 antibody directed to the V5 tag on the transfected MMP-8. Lower panel:
Collagen-I zymography. CM was collected from the β6-1089 cells as described above and concentrated 20× using 3 K spin columns. Equal
volumes were run by SDS-PAGE containing 3 mg of Collagen-I. The gel was incubated overnight in substrate solution and then stained with
Coomassie. Only the lane containing CM from β6-1089 transfected with WT MMP-8 demonstrated a clear band indicating Collagen degradation
at the same molecular weight as MMP-8. b (i) Adhesion to ECM proteins. β6-1089 cells transiently transfected with empty vector (EMPTY), wild-
type MMP-8 (WT) or inactive mutant MMP-8 (EA) were plated on Fibronectin (Fib), Collagen-I (Col-I), Collagen-IV (Col-IV), Laminin-I (Lam-I),
Tenascin-C (Ten-C), latency-associated peptide (LAP) or BSA (Control) for 1 hour. Then cells were treated with Calcein AM for 15 minutes before
reading the fluorescence. The adhesion is calculated relative to the EMPTY. Expression of WT MMP-8 increased cell adhesion to Fib, Col-I, Lam-I
and Ten-C, and decreased adhesion to LAP. The EA transfected cells did not show alterations in adhesion.(ii) β6-1089 cells treated in the same
way as above were plated onto transwells coated on the underside with the same ECM proteins and cells were allowed to migrate for 8 hours
before quantifying the number of cells that were on the top and bottom of the transwell. Migration was calculated relative to the EMPTY.
Expression of WT MMP-8 decreased migration towards Fib, Col-I, Lam-I, Ten-C and LAP, while expression of the EA had no effect. c (i) N-1089 cells
were transfected with siRNA targeting MMP-8 (siMMP-8) or Luciferase (siLuc) as a control. Ninety-six hours after transfection protein and RNA were
collected and analysed by western blot and RT Q-PCR respectively. Both the western blot (upper panel) and RT Q-PCR (graph) indicate a reduction
in MMP-8 at the protein and mRNA level in response to siMMP-8 treatment as compared to the siLUC control. (ii) N-1089 cells treated with
siMMP-8 as described were plated onto the same selection of ECM proteins as previously described in (b). A significant reduction in adhesion to
Fib, Col-I, Col-IV, Lam-I and Ten-C was observed in N-1089 transfected with siMMP-8 as compared to N-1089 transfected with siLUC. (iii) N-1089
cells treated with siMMP-8 were also plated on transwells coated with the same selection of ECM proteins as described in (b). The N-1089
transfected with siMMP-8 demonstrated a significant increase in migration towards Col-IV, Lam-I and Ten-C as compared to N-1089 + siLUC.
**p = 0.01, ***p = 0.001 (Student’s t test). Error bars = SEM, n = 3 independent experiments
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during early invasion through basement membrane,
MDA-MB-231 or SUM159 breast cancer cells were
seeded onto transwells coated with Matrigel and co-cultured with β6-1089 cells expressing MMP-8 WT,
MMP-8 EA or empty vector control plated onto outer
chamber for 24 hours (Fig. 4). A significant reduction in
the number of breast cancer cells invading through
Fig. 3 (See legend on next page.)
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Fig. 3 MMP-8 expression alters α6β4 subcellular distribution and myoepithelial cell morphology. a (i) Confocal images of β6-1089 cells transfected
with empty vector (EMPTY) wild-type matrix metalloproteinase-8 (MMP-8 WT) or inactive mutant MMP-8 (EA) and grown on Fibronectin for 24
hours then fixed and co-stained for α6β4 (red) and plectin (green). Insert: cartoon illustrating hemidesmosome (HD) components, indicating the
integrin α6β4 associates with plectin to link the complex to the keratin cytoskeleton. (ii) Co-localisation of α6β4 and plectin was determined by
quantifying the number of yellow pixels per field of view in each condition then expressed as a ratio as compared to EMPTY. β6-1089 transfected
with WT demonstrated a significant increase in α6β4 and plectin co-localisation, while the β6-1089 transfected with EA exhibited no change as
compared to EMPTY. b (i) Confocal images of β6-1089 cells transfected with empty vector (EMPTY) wild-type MMP-8 (WT) or inactive mutant
MMP-8 (EA) and grown on Fibronectin for 24 hours then fixed and co-stained for α6β4 (green) and phallodin (red). (ii) Morphological features of
the transfected β6-1089 were analysed and length of trailing fibres was noted to be altered. Analysis of the length of these fibres indicated that
β6-1089 transfected with MMP-8 WT significantly reduced the fibre length as compared to β6-1089 transfected with empty vector or MMP-8 EA.
(iii) Analysis of the number of these fibres per cell also demonstrated a significant reduction in β6-1089 transfected with MMP-8 WT as compared
to β6-1089 transfected with empty vector or MMP-8 EA. (iv) The final morphological alteration analysed was the physical space the cells occupied,
the relative area occupied by β6-1089 transfected with MMP-8 WT was significantly larger than that occupied by β6-1089 transfected with empty
vector or MMP-8 EA. c (i) Confocal images of N-1089 cells transfected with siRNA targeting MMP-8 (siMMP-8) or Luciferase (siLuc) as a control
grown on Fibronectin for 24 hours then fixed and co-stained for α6β4 (green) and phallodin (red). (ii) Trailing fibre length was significantly longer
in N-1089 transfected with siMMP8 as compared to siLUC. (iii) There were significantly more trailing fibres per cell in the N-1089 + siMMP8 group
as compared to N-1089 transfected with siLUC. *p = 0.05 **p = 0.01, ***p = 0.001 (Student’s t test). Error bars = SEM, n = 3 independent experiments
Fig. 4 MMP-8 expression by myoepithelial cells has a paracrine effect on tumour cell invasion. a β6-1089 cells transfected with empty vector
(EMPTY) wild-type matrix metalloproteinase-8 (MMP-8 WT) or inactive mutant MMP-8 (EA) were plated into 24-well plates and grown in serum-
free media for 24 hours. Transwells coated with Matrigel were placed into the wells and MDA-MB-231 or SUM159 cells were placed on top of the
Matrigel. After 24 hours the transwells were removed and the number of invading cancer cells counted. Invasion was calculated relative to the
β6-1089 transfected with empty vector. MDA-MB-231 and SUM159 cells exhibited a significant reduction in invasion when in the presence of β6-
1089 transfected with WT cells, this was not observed with the β6-1089 transfected with EA cells. b MTS assay for viability on MDA-MB-231 and
SUM159 cells grown for 24 hours in the presence of conditioned media (CM) from β6-1089 cells transfected with empty vector (EMPTY) wild-type
MMP-8 (WT) or inactive mutant MMP-8 (EA). No difference was observed between any of the groups relative to β6-1089 transfected with empty
vector. c Transwells were set up as described above with N-1089 cells transfected with siRNA targeting MMP-8 (siMMP-8) or Luciferase (siLuc) were
plated into the bottom wells. MCF-7, MDA-MB-231 and SUM159 cells were plated into Matrigel-coated transwells above. After 24 hours (or 48
hours for MCF-7) the transwells were removed and the number of invading cancer cells counted. Invasion was calculated relative to the N-1089
transfected with siLUC. MDA-MB-231 and SUM159 cells exhibited a significant increase in invasion when in the presence of N-1089 transfected
with siMMP-8. d MTS assay for viability on MCF-7, MDA-MB-231 and SUM159 cells grown for 24 hours in the presence of conditioned media (CM)
from N-1089 cells transfected with siRNA targeting MMP-8 (siMMP-8) or Luciferase (siLuc). No difference was observed between the two groups.
**p = 0.01, (Student’s t test). Error bars = SEM, n = 3 independent experiments
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MMP-8 WT was observed compared to cells transfected
with EA or empty vector (Fig. 4a). Transwells carried
out using ER+ cell line MCF-7 showed no reduction in
invasion (data not shown) – however these cells exhib-
ited a low degree of invasion and therefore it can be
speculated that the invasion could not be reduced any
further. These results indicate that the invasion-
suppressor activity exhibited by MMP-8 WT MECs is
dependent upon MMP-8 enzymatic activity, as MMP-8
EA does not influence tumour cell invasion. To show a
direct effect of MMP-8 on breast cancer cell invasion,
recombinant MMP-8 containing serum-free media was
used in the outer chamber, which resulted in a signifi-
cant decrease in breast cancer cell invasion similar to
that seen with MMP-8 WT MECs (data not shown). In
order to eliminate the possibility that the reduced inva-
sion was a reflection of altered cell number of breast
cancer cells, MDA-MB-231 and SUM159 cells were
treated with CM collected from modified MECs after 24
hours of starvation (the same time duration as the inva-
sion assays). The tumour cells were analysed in an MTS
assay, which revealed no differences in relative cell num-
ber of the MDA-MB-231 or SUM159 cells (Fig. 4b).
When the MMP-8 substrate Col-I was replaced with
Matrigel in transwell invasion assays, there also was a
significant downregulation in breast cancer cell invasion
towards MMP-8 WT over-expressing β6-1089 cells, but
not MMP-8 EA or empty vector transfected cells (data
not shown).
To dissect whether loss of normal MEC-derived MMP-
8 has an influence on breast cancer cell invasion, MCF-7,
MDA-MB-231 and SUM159 cells were co-cultured with
N-1089 control cells following knock-down of MMP-8 in
a transwell setup. This demonstrated that breast cancer
cell invasion was significantly enhanced in the absence of
MMP-8 (Fig. 4c). These data support the earlier conten-
tion that reduction in MCF-7 invasion was too small to
measure, as co-culturing with MECs knocked down for
MMP-8 enhanced MCF-7 invasion significantly. No
significant difference in breast cancer cell number was
demonstrated in the presence of N-1089 control or
MMP-8 knock-down CM (Fig. 4d), supporting the con-
cept that MMP-8 suppresses invasion and does not alter
cell number.
Myoepithelial MMP-8 WT suppresses breast cancer cell
invasion in 3D organotypic culture
In order to recapitulate the DCIS-related stromal micro-
environment, 3D organotypic cultures were constructed
from Col-I/Matrigel gels embedded with primary normal
breast fibroblasts and overlaid with modified MECs and
MDA-MB-231 or SUM159 breast cancer cells, to reflect
the juxtapositioning of these cell populations in breasttissue (Fig. 5). After 10 days of incubation, gels were
fixed, sectioned and stained with hematoxylin and eosin
(H&E) (Fig. 5a). In order to discriminate the invading
breast cancer cells from modified β6-1089 cells, organo-
typic cultures were stained for the invasive breast cancer
cell marker Neso [46], which selectively detects the
tumour cells invading into the gel (Additional file 4:
Figure S2). An invasion index was quantified by combin-
ing the depth, number and area occupied by invaded
cells and normalised to invasion observed when breast
cancer cells were co-cultured with β6-1089 cells trans-
fected with empty vector control. There was a significant
decrease in tumour cell invasion only in the presence of
MMP-8 WT transfected β6-1089 cells (Fig. 5b). To
confirm that the reduced invasion index does not reflect
decreased proliferation, organotypic gels were stained
for the proliferation marker Ki67. The Ki67 index indi-
cates that proliferation is not significantly altered in any
of the transfection groups (Fig. 5c).
MMP-8 modifies MMP-9 activity
We previously have identified increased MMP-9 activity
in β6-1089 cells compared to N-1089, downstream of
enhanced TGF-β signalling [41]. Furthermore it has
been reported that MMP-9 can cleave the extracellular
domain of α6β4 and in turn interfere with HD assembly
[47]; we therefore analysed the expression levels and
proteolytic function of MMP-9 in β6-1089 cells, with
and without MMP-8 over-expression. RT Q-PCR re-
vealed no significant difference in MMP-9 mRNA levels
between empty, MMP-8 WT or MMP-EA transfected
cells (data not shown). To study whether the proteolytic
activity of MMP-9 is altered upon MMP-8 expression,
modified β6-1089 cells were grown on rhodamine-
labelled MMP-9 substrate gelatin for 24 hours and then
fixed and stained with FITC-conjugated phalloidin. The
degraded matrix area was quantified, and demonstrated
a significant reduction in gelatin degradation in β6-1089
cells transfected with MMP-8 WT compared to the EA
form or empty vector (Fig. 6a i and ii). There was no
difference in cell number per field among different
transfection groups (Fig. 6a iii).
In order to understand whether MMP-8 loss in N-
1089 cells can influence MMP-9 function, modified N-
1089 cells were seeded on MMP-9 substrate as described
and gelatinase activity was quantified. The area of de-
graded gelatin was significantly increased in MMP-8
knocked down cells, with no change in cell number
(Fig. 6b i-iii).
To further investigate the MMP-9 activity, MMP-9 was
knocked down by siRNA treatment in the MMP-8
knocked down N-1089 cells (MMP-9 knock-down was
verified by RT Q-PCR, data not shown) or cells were
treated with an MMP-9 inhibitor (Fig. 6c). Gelatin
Fig. 5 MMP-8 expression in myoepithelial cells alters tumour cell invasion in 3D organotypics. a 3D organotypic microenvironment of the breast
was created by mixing collagen and Matrigel with normal breast fibroblasts. β6-1089 cells transfected with empty vector (EMPTY) wild-type matrix
metalloproteinase-8 (MMP-8 WT) or inactive mutant MMP-8 (EA) were plated on top of the gel and allowed to attach, then MDA-MB-231 cells
were plated on top of the transfected β6-1089 cells. Organotypics were grown at an air/liquid interface for 10 days then fixed and embedded in
paraffin. Section were taken and stained with H&E and images were taken for analysis. b An invasion index was determined for each condition by
multiplying; the average depth of invasion (from multiple points in each section), the number of invading aggregates and the size of the
aggregates. MDA-MB-231 cells grown with β6-1089 transfected with WT exhibited a significantly reduced invasion index relative to the β6-1089
transfected with EMPTY and EA. c Organotypic sections were stained for Ki67 and the positively staining cells were quantified to determine the
level of proliferation in each condition. There was no difference observed between any of the groups. ***p = 0.001 (Student’s t test). Error
bars = SEM, n = 3 independent experiments
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9 knock-down in siMMP-8-treated N-1089 cells. In
addition, there was a dose-dependent decrease in de-
graded gelatin area in relation to increasing concentrations
of MMP-9 inhibitor. There was no difference in gelatin
degradation in DMSO vehicle control compared to
siMMP-8 treatment suggesting that the increased gelatin
degradation is derived from increased MMP-9 activity
after MMP-8 knock-down.
MMP-8 reduces TGF-β signalling
To study the effect of MMP-8 expression on TGF-β
ignalling, modified β6-1089 cells were treated with 5 ng/
ml active TGF-β1 for 5, 10 and 15 minutes. As a readout
for TGF-β signalling activity, the phosphorylation levels
of TGF-β downstream element SMAD-2 was evaluated
by WB. The expression levels of total and phosphory-
lated forms of SMAD-2 were normalised to that of actin.
The phosphorylation levels of SMAD-2 were decreased
in β6-1089 cells over-expressing MMP-8 WT as com-
pared to empty vector control and EA mutant cells at 5minutes. There also was a reduction in phospho-SMAD-
2 in β6-1089 cells over-expressing MMP-8 EA as
compared to empty vector at 15 minutes. The phosphor-
ylation levels of SMAD-2 in MMP-8 EA were higher
than phospho-SMAD-2 levels in MMP-8 WT at 5 mi-
nutes (Fig. 6d i and Additional file 5: Figure S3i).
To investigate the effect of loss of MMP-8 on TGF-β
downstream signalling, modified N-1089 cells, with
MMP-8 knock-down, were treated with active TGF-β1
as described. This revealed an increase in phosphory-
lated SMAD-2 in MMP-8 knocked-down N-1089 cells
compared to control siRNA transfected cells at 5, 10 and
15 minutes (Fig. 6d ii and Additional file 5: Figure S3ii),
suggesting that MMP-8 reduces TGF-β signalling, and
this may not be dependent on enzymatic activity.
Discussion
Transition of DCIS to invasive cancer is a critical step in
the natural history of breast cancer, converting a poten-
tially curable lesion to a life-threatening disease. Only
around half of DCIS lesions will progress to invasive
Fig. 6 (See legend on next page.)
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Fig. 6 MMP-8 expression in myoepithelial cells alters MMP-9 expression/function and TGF-β signalling. a (i) Confocal images of β6-1089 cells
transfected with empty vector (EMPTY) wild-type matrix metalloproteinase-8 (MMP-8 WT) or inactive mutant MMP-8 (EA) and grown on
rhodamine-tagged gelatin (red) for 24 hours then fixed and stained with FITC-conjugated phallodin (green). (ii) Gelatinase activity was quantified
by measuring the total size of the black spots (degraded gelatin) per field of view relative to the β6-1089 transfected with EMPTY. There was a
significant reduction in gelatin degradation in β6-1089 transfected with WT and EA compared to β6-1089 transfected with EMPTY, albeit the
reduction in β6-1089 transfected with EA was not as marked. (iii) The number of cells per field of view was determined and no significant
difference was noted between the groups. b (i) Confocal images of N-1089 cells transfected with siRNA targeting MMP-8 (siMMP-8) or Luciferase
(siLuc) and grown on rhodamine-tagged gelatin (red) for 24 hours then fixed and stained with FITC-conjugated phallodin (green). (ii) Gelatin
degradation was significantly increased in N-1089 transfected with siMMP-8 as compared to siLUC. (iii) Quantification of the number of cells per
field of view indicated no difference between the two groups. c Confocal images of N-1089 cells transfected with siRNA targeting MMP-8
(siMMP-8) and MMP-8 and MMP-9 (siMMP-8/9) or Luciferase (siLuc) and grown on rhodamine-tagged gelatin (red) for 24 hours with or without
an MMP-9 inhibitor at increasing concentration then fixed and stained with FITC-conjugated phallodin (green). The graph indicates relative gelatin
degradation increases in N-1089 transfected with siMMP-8, this increase is significantly reduced when both MMP-8 and MMP-9 are knocked down
(siMMP-8/9). The increase in gelatin degradation can also be significantly reduced, in a dose-dependent manner, with an MMP-9 inhibitor. d (i) Western
blots for SMAD-2 on protein extracted from β6-1089 cells transfected with empty vector (EMPTY), wild-type MMP-8 (WT) or inactive mutant MMP-8
(EA) after treatment with TGF-β (5 ng/ml) for 5, 10 and 15 minutes. β6-1089 transfected with empty vector exhibit higher levels of Phospho (p)SMAD-2
at all time points than the β6-1089 transfected with WT, while the β6-1089 transfected with EA appear to show moderate expression. Total (t)SMAD-2
levels are similar in all lanes as is the actin loading control. (ii) Western blots for SMAD-2 on protein extracted from of N-1089 cells transfected with
siRNA targeting MMP-8 (siMMP-8) or Luciferase (siLuc) after treatment with TGF-β (5 ng/ml) for 5, 10 and 15 minutes. N-1089 transfected with siMMP-8
exhibit higher expression of pSMAD-2 at 10 and 15 minutes than the N-1089 transfected with siLUC. The tSMAD2 and actin expression levels appear
to be consistent. *p = 0.05 **p = 0.01, ***p = 0.001 (Student’s t test). Error bars = SEM, n = 3 independent experiments
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robust predictive markers to stratify patient management
[1, 48, 49]. Molecular studies have indicated a consistent
similarity between DCIS tumour cells and their invasive
counterparts, showing that DCIS cells are as genetically
advanced as invasive cancer. This has focused attention
on the microenvironment, which shows evidence of
being significantly altered in DCIS compared to normal
tissue [6, 7, 50, 51]. A unique component of the breast
microenvironment is the MEC population. In the normal
breast, MECs form a stable interface with the basement
membrane, regulate epithelial cell polarity and exert a
multifaceted tumour-suppressor role [9, 52–55]. We,
and others, have shown that MECs are altered in DCIS
and we recently demonstrated that upregulation of the
integrin αvβ6 by DCIS-associated MEC confers tumour-
promoter activity on MECs through TGF-β-mediated
upregulation of MMP-9 [27].
Whilst many MMPs exert tumour-promoter effects, a
greater understanding of metalloproteinase biology has
indicated that some family members have tumour-
suppressor effects. MMP-8 was identified as a tumour
suppressor nearly a decade ago when the MMP-8 knock-
out mouse was found to be more susceptible to skin
tumuorigenesis as compared to a WT mouse [28]. There
is also strong evidence for a role in tumour prevention in
breast cancer, melanoma and squamous cell carcinoma
[22, 26, 28, 29, 31, 32, 56–59]. Particularly in melanoma;
MMP-8 is frequently mutated by loss of heterozygosity
(LOH), which is a hallmark for tumour-suppressor pro-
teins [22]. In addition this mutation results in a significant
decrease in enzymatic activity and a concomitant loss of
its cancer-protective role [26]. However understandingthe mechanism by which MMP-8 mediates this anti-
tumour role is incomplete. In the breast, MMP-8 is
expressed by the MEC population, and we identified
loss of MMP-8 in DCIS-associated MECs [22]. This
study aimed to address the role of MMP-8 in MECs
and the impact of its loss on MEC phenotype and
tumour-suppressor function.
We used purified cell populations from normal and
diseased breast to confirm MECs as the primary source
of MMP-8 in the normal breast, and its loss in DCIS-
associated MECs. We demonstrated similar loss of ex-
pression in a cell line model of DCIS-associated MEC
generated by over-expression of β6 integrin (β6-1089
cells) compared to its normal MEC counterpart (N-
1089). These models were used to investigate gain-of-
function effects, through over-expression of MMP-8 or
an inactive mutant (EA, which carries a point mutation
in catalytic site) in β6-1089, and loss-of-function effects,
through MMP-8 knock-down in N-1089 cells.
In normal breast, MECs have a central role in preserv-
ing normal tissue architecture, [60], and correct MEC-
matrix interactions are crucial for MECs to maintain cell
polarity in the context of tumour suppression [52–54, 61].
We therefore aimed to investigate if MMP-8 is involved in
ECM sensing and response.
When modified β6-1089 cells were seeded on different
ECM components, WT MMP-8 but not the inactive
MMP-8 EA resulted in a significant increase in MEC
adhesion to ECM proteins including Fibronectin,
Collagen-I, Laminin-I and Tenascin-C. Furthermore,
transwell migration assays indicated that MEC migration
towards Fibronectin, Collagen-I, Laminin-I and Tenascin-
C was significantly downregulated only in MMP-8 WT
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age of MECs to ECM, reflecting their role in normal
breast. Both adhesion to and migration towards LAP, an
established ligand of αvβ6 integrin [42], was consistently
and significantly reduced, possibly reflecting a reduction
in αvβ6 integrin activity. Similarly, knock-down of MMP-
8 in N-1089 cells resulted in decreased adhesion and
enhanced migration to ECM proteins, confirming a role
for MMP-8 in matrix adhesion.
MEC attachment to basement membrane is achieved
through HDs, which are stable adhesions critical for the
integrity of epithelial cell monolayers. The integrin α6β4
nucleates HD formation through linkage to plectin and
the intermediate filament cytoskeleton [43, 62]. Disasso-
ciation of HDs and localisation of α6β4 to actin-rich
protrusions are characteristics of the acquisition of a
migratory phenotype in basal cells, and has been well
studied in migrating keratinocytes during wound healing
[63–65]. Since loss of HD formation is recognised in
DCIS-associated MEC [43], we sought to investigate the
effect of MMP-8 on the subcellular localisation of α6β4.
This revealed that, in MMP-8 WT over-expressing cells,
there was significantly greater co-localisation of α6β4 to
HD-associated plectin, with shorter and reduced number
of retraction fibres, corresponding to a reduced migratory
phenotype. Moreover, phalloidin staining of modified β6-
1089 cells showed that MMP-8 WT cells significantly
spread more on Fibronectin, in keeping with a more adhe-
sive phenotype. In keeping with this, knock-down of
MMP-8 in N-1089 cells resulted in significantly longer
and increased number of retraction fibres compared to
control cells, which we speculate indicates the acquisition
of a more migratory phenotype.
Compromise of the MEC-basement membrane barrier
is a key event in progression of DCIS to invasive cancer.
Since MMP-8 impacts on MEC adhesion and HD for-
mation, we sought to analyse whether altered MMP-8
expression by MEC influences their tumour-suppressor
activity. Transwell invasion assays were used, in which
MCF-7, MDA-MB-231 or SUM159 breast cancer cells
were placed onto a Matrigel-coated porous membrane
and allowed to invade towards MEC populations. A
significant decrease in tumour invasion was observed for
MDA MD 231 and SUM159 cells co-cultured with
MMP-8 WT over-expressing β6-1089 compared to
empty vector and MMP-8 EA, suggesting that MMP-8
contributes to MEC invasion-suppressor effect. This was
further supported by enhanced transwell invasion for all
tumour cells in the presence of N-1089 MMP-8 knock-
down cells. A similar effect was detected in a more
physiologically relevant 3D organotypic model reflecting
the microenvironmental conditions of DCIS, incorporat-
ing a fibroblast populations as well as the MEC-tumour
cell bilayer [41, 66].Cooperation of tumour cells with the microenvironment
is required to breach basement membrane [19, 62, 67].
Thus altered proteolytic activity of MECs could contribute
to the invasive phenotype of breast cancer cells. We previ-
ously have shown that β6-1089 cells promote tumour in-
vasion through TGF-β-mediated upregulation of MMP-9
[41]. A number of studies have indicated that MMP-8 can
modulate TGF-β signalling [68, 69], and since we show
that over-expression of MMP-8 WT in β6-1089 cells
modifies their invasion-promoter effect, we investigated
whether MMP-8 could influence TGF-β signalling and
MMP-9 expression or activity in this cell population. This
showed that phosphorylation of SMAD-2 was downregu-
lated in β6-1089 cells expressing MMP-8 WT and en-
hanced in N-1089 cells following MMP-8 knock-down,
supporting a role for MMP-8 in dampening TGF-β signal-
ling. However, MMP-8 WT or EA did not have a signifi-
cant effect on MMP-9 expression, though when modified
β6-1089 cells were incubated on fluorescently labelled gel-
atin, the substrate of MMP-9, the area of degradation was
significantly abrogated by MMP-8 WT cells. In contrast,
gelatin degradation was significantly enhanced by knock-
down in N-1089 cells, and importantly this effect could be
rescued by MMP-9 inhibition or by MMP-9 knock-down.
This suggests some form of inhibitory interaction between
MMP-8 and MMP-9: it previously has been shown that
MMP-8 can establish a complex with MMP-9 but the
function of this complex remains elusive [30].
In tissues MECs of normal and benign ducts are con-
sistently positive for MMP-8, whilst there is a significant
progressive loss of this metalloproteinase through pure
DCIS to DCIS with co-existing invasion (p = 0.001,
Additional file 2: Table S2). This finding should be fur-
ther validated on a larger cohort ideally with long-term
follow-up.Conclusions
Overall these data indicate that MEC-derived MMP-8 acts
as a tumour suppressor by promoting HD formation and
enhancing cell adhesion to ECM, thus maintaining tissue
architecture, and concomitantly downregulating breast
cancer cell invasion in a proteolytic-dependent manner.
MMP-8 appears to downregulate the TGF-β signalling
evident in DCIS-associated MEC, and opposes MMP-
9 activity, which we show promotes breast cancer cell
invasion [27] and also has been shown to prevent HD
formation [43].
Since both αvβ6 integrin [27] and MMP-8 are key
regulators of myoepithelial pro- and anti-tumorigenic
activity, these data support the development of a risk
stratification profile that could be used clinically to tailor
management of patients with DCIS. This is an approach
currently being addressed by the LORIS trial [70].
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Additional file 1: Table S1. Summary of breast tissue examined for
MMP8. (DOC 27 kb)
Additional file 2: Table S2. Duct-by-duct analysis. (DOC 28 kb)
Additional file 3: Figure S1. Dual immunofluorescent staining of a
normal breast duct showing MMP-8 (green Atlas, HPA02122,1:200) and p63
(red Abcam, Ab735, 1:50). The image shows predominant myoepithelial
localisation of MMP-8. (TIF 7068 kb)
Additional file 4: Figure S2. Images of one representative organotypic
gel fluorescently stained for myoepithelial marker p63 (green) (non-
invading cell layer), nuclear marker DAPI (blue) and marker of invasive
breast cancer cells Neso (red). From left to right images show gels
comprising fibroblasts, MDA-MB-231 cells and MECs transfected with
Empty Vector, MMP8 WT and MMP8 EA. The final panel shows a gel
comprised of fibroblasts and MECs alone. Non-transfected MECs were
used in the last panel. (TIF 986 kb)
Additional file 5: Figure S3. (i) Densitometry quantifying pSMAD2
versus tSMAD2 normalised to the loading control. MECs transfected with
MMP-8 WT show a marked reduction of pSMAD2 compared to Empty
Vector and MMP-8 EA at 5 minutes. (ii) Densitometry quantifying pSMAD2
versus tSMAD2 normalised to the loading control. MECs transfected with
siRNA to MMP-8 demonstrated a markedly stronger pSMAD2 signal
compared to control siRNA (siLUC). (TIF 336 kb)
Abbreviations
CM: Conditioned media; Col-I: Collagen-I; Col-IV: Collagen-IV; DCIS: Ductal
carcinoma in situ; EA: Inactive mutant; ECM: Extracellular matrix;
Fib: Fibronectin; HD: Hemidesmosomes; IBC: Invasive breast cancer; Lam-
I: Laminin-I; LAP: Latency-associated peptide; LEC: Luminal epithelial cell;
MEC: Myoepithelial cell; MMP-8: Matrix metalloproteinase-8; SFM: Serum-free
media; Ten-C: Tenascin-C; TGF-β: Transforming growth factor beta; WT: Wild-
type
Acknowledgements
We give special thanks to all of the patients who consented to provide us with
material, without their cooperation this study could not have been done.
Funding
MS was funded by a Breast Cancer Now (formerly Breast Cancer Campaign)
PhD studentship. JG and LH are funded as part of the Breast Cancer Now
Tissue Bank Cell Culture Programme.
Availability of data and materials
All data generated or analysed during this study are included in this
published article and its supplementary information files. The patient cases
dataset used is not publically available for data protection, but is available
from the corresponding author on reasonable request.
Authors’ contributions
MS and MA participated in the design of the study, carried out the experiments,
analysed the data and drafted the manuscript. AU carried out MMP8 IHC and
helped with analysis. JG and LH characterised and provided the primary cells for
the experiments. JD and ST provided MMP-8 WT and MMP-8 EA vectors and
provided input to the experimental design. JFM provided expertise in organotypic
assays and in the in situ zymography, as well as critical evaluation of
the manuscript. S-JS provided statistical analysis support. DRE and JLJ
were joint PIs of the study, participating in the design and critical evaluation of





The authors declare they have no competing interests.
Consent for publication
No individual level data are presented in this manuscript.Ethics approval and consent to participate
Breast tissue samples were obtained from surgical specimens from patients
undergoing breast surgery at Barts Health NHS Trust London. The study was
performed following patient consent and approval from the local research
ethics committee (reference: 05/Q0403/199 and 09/H075/39).Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Translational Cancer Discovery Team, CRUK Cancer Therapeutics Unit,
Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
2Centre for Tumour Biology, Barts Cancer Institute, John Vane Science Centre,
Charterhouse Square, Queen Mary University of London, Charterhouse
Square, London EC1M 6BQ, UK. 3Cancer Research Centre, Qatar Biomedical
Research Institute, Qatar Foundation, Doha, Qatar. 4Centre for Experimental
Cancer Medicine, Barts Cancer Institute, John Vane Science Centre,
Charterhouse Square, Queen Mary University of London, Charterhouse
Square, London EC1M 6BQ, UK. 5School of Biological Sciences, University of
East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK.
Received: 28 September 2016 Accepted: 2 March 2017References
1. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in
situ of the breast. N Engl J Med. 2004;350(14):1430–41.
2. Hannemann J, Velds A, Halfwerk JBG, Kreike B, Peterse JL, van de Vijver MJ.
Classification of ductal carcinoma in situ by gene expression profiling. Breast
Cancer Res. 2006;8:R61.
3. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis.
Cancer Metastasis Rev. 2006;25:9–34.
4. Jorgensen KJ, Gotzsche PC. Breast screening: fundamental errors in estimate
of lives saved by screening. Br Med J. 2009;339.
5. Payne SJL, Bowen RL, Jones JL, Wells CA. Predictive markers in breast
cancer–the present. Histopathology. 2008;52:82–90.
6. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T,
Pistone M, Stecker K, Zhang BM, et al. Gene expression profiles of human
breast cancer progression. Proc Natl Acad Sci U S A. 2003;100(10):5974–9.
7. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular
subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive
disease. Br J Cancer. 2010;104:120–7.
8. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J,
Richardson A, Cooper A, Strausberg R, Riggins GJ, et al. Molecular markers in
ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362–75.
9. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter
D, Hu M, Chin L, Richardson A, et al. Molecular characterization of the
tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.
10. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo
W-L, Ljung B-M, Chew K, Myambo K, et al. In situ analyses of genome
instability in breast cancer. Nat Genet. 2004;36:984–8.
11. Yao J, Weremowicz S, Feng B, Gentleman RC, Marks JR, Gelman R, Brennan
C, Polyak K. Combined cDNA array comparative genomic hybridization and
serial analysis of gene expression analysis of breast tumor progression.
Cancer Res. 2006;66(8):4065–78.
12. Jones JL, Royall JE, Critchley DR, Walker RA. Modulation of myoepithelial-
associated alpha6beta4 integrin in a breast cancer cell line alters invasive
potential. Exp Cell Res. 1997;235(2):325–33.
13. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells
exert an invasion-suppressor effect on breast cancer cells via paracrine down-
regulation of MMP expression in fibroblasts and tumour cells. J Pathol. 2003;
201:562–72.
14. Barsky SH, Karlin NJ. Myoepithelial cells: autocrine and paracrine
suppressors of breast cancer progression. J Mammary Gland Biol
Neoplasia. 2005;10:249–60.
15. Sternlicht MD, Kedeshian P, Shao ZM, Safarians S, Barsky SH. The human
myoepithelial cell is a natural tumor suppressor. Clin Cancer Res. 1997;3(11):
1949–58.
Sarper et al. Breast Cancer Research  (2017) 19:33 Page 18 of 1916. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A,
Violette S, Nikolskaya T, Nikolsky Y, et al. Regulation of in situ to invasive
breast carcinoma transition. Cancer Cell. 2008;13:394–406.
17. Barsky S. Myoepithelial mRNA expression profiling reveals a common
tumor-suppressor phenotype. Exp Mol Pathol. 2003;74:113–22.
18. Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, Polyak K.
Distinct epigenetic changes in the stromal cells of breast cancers. Nat
Genet. 2005;37:899–905.
19. Polyak K, Kalluri R. The Role of the microenvironment in mammary gland
development and cancer. Cold Spring Harb Perspect Biol. 2010;2:a003244.
20. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good
fences make good neighbors. Breast Cancer Res. 2005;7(5):190–7.
21. Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive.
Cytokine Growth Factor Rev. 2006;17:217–23.
22. Gutiérrez-Fernández A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ,
Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, et al. Matrix
metalloproteinase-8 functions as a metastasis suppressor through modulation
of tumor cell adhesion and invasion. Cancer Res. 2008;68:2755–63.
23. Bachmeier BE, Iancu CM, Jochum M, Nerlich AG. Matrix metalloproteinases
in cancer: comparison of known and novel aspects of their inhibition as a
therapeutic approach. Expert Rev Anticancer Ther. 2005;5(1):149–63.
24. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the
tumor microenvironment. Cell. 2010;141:52–67.
25. Lafleur MA, Handsley MM, Edwards DR. Metalloproteinases and their
inhibitors in angiogenesis. Expert Rev Mol Med. 2004;5(23):1–39.
26. Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis
S, Wang C, Cronin JC, Agrawal NS, et al. Analysis of the matrix
metalloproteinase family reveals that MMP8 is often mutated in melanoma.
Nat Genet. 2009;41:518–20.
27. Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ,
Dreger SA, Dickinson S, Edwards DR, et al. Altered microenvironment
promotes progression of preinvasive breast cancer: myoepithelial expression
of alphavbeta6 integrin in DCIS identifies high-risk patients and predicts
recurrence. Clin Cancer Res. 2014;20(2):344–57.
28. Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A, Overall CM,
Shapiro SD, López-Otín C. Loss of collagenase-2 confers increased skin
tumor susceptibility to male mice. Nat Genet. 2003;35:252–7.
29. Korpi JT, Kervinen V, Mäklin H, Väänänen A, Lahtinen M, Läärä E, Ristimäki A,
Thomas G, Ylipalosaari M, Aström P, et al. Collagenase-2 (matrix
metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer.
2008;98:766–75.
30. Gutiérrez-Fernández A, Inada M, Balbín M, Fueyo A, Pitiot AS, Astudillo A,
Hirose K, Hirata M, Shapiro SD, Noël A, et al. Increased inflammation delays
wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J. 2007;
21:2580–91.
31. Decock J, Long J-R, Laxton RC, Shu X-O, Hodgkinson C, Hendrickx W, Pearce
EG, Gao Y-T, Pereira AC, Paridaens R, et al. Association of matrix
metalloproteinase-8 gene variation with breast cancer prognosis. Cancer
Res. 2007;67:10214–21.
32. Decock J, Hendrickx W, Thirkettle S, Gutierrez-Fernandez A, Robinson SD,
Edwards DR. Pleiotropic functions of the tumor- and metastasis-suppressing
matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic
mice. Breast Cancer Res. 2015;17:38.
33. Tester AM, Cox JH, Connor AR, Starr AE, Dean RA, Puente XS, Lopez-Otin C,
Overall CM. LPS responsiveness and neutrophil chemotaxis in vivo require
PMN MMP-8 activity. PLoS One. 2007;2(3):e312.
34. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker
G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the
chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX
and modulate their physiological activities. Eur J Biochem. 2003;270(18):
3739–49.
35. Cox JH, Dean RA, Roberts CR, Overall CM. Matrix metalloproteinase
processing of CXCL11/I-TAC results in loss of chemoattractant activity and
altered glycosaminoglycan binding. J Biol Chem. 2008;283(28):19389–99.
36. Pellinen T, Rantala JK, Arjonen A, Mpindi JP, Kallioniemi O, Ivaska J. A
functional genetic screen reveals new regulators of beta 1-integrin activity.
J Cell Sci. 2012;125(3):649–61.
37. Quintero PA, Knolle MD, Cala LF, Zhuang Y, Owen CA. Matrix
metalloproteinase-8 inactivates macrophage inflammatory protein-1 alpha
to reduce acute lung inflammation and injury in mice. J Immunol. 2010;
184(3):1575–88.38. Gomm JJ, Browne PJ, Coope RC, Liu QY, Buluwela L, Coombes RC. Isolation
of pure populations of epithelial and myoepithelial cells from the normal
human mammary-gland using immunomagnetic separation with
Dynabeads. Anal Biochem. 1995;226(1):91–9.
39. Thirkettle S, Decock J, Arnold H, Pennington CJ, Jaworski DM, Edwards DR.
Matrix metalloproteinase 8 (collagenase 2) induces the expression of
interleukins 6 and 8 in breast cancer cells. J Biol Chem. 2013;288(23):16282–94.
40. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature. 2001;411(6836):494–8.
41. Allen M, Mulligan K, Clark S, Hart I, Marshall JF, Jones JL. De novo expression of
alpha(v)beta(6) integrin by myoepithelial cells in ductal carcinoma in situ may be
an important marker of disease progression. Breast Cancer Res. 2008;10:S16–6.
42. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF,
Kaminski N, Garat C, Matthay MA, et al. The integrin alpha v beta 6 binds
and activates latent TGF beta 1: a mechanism for regulating pulmonary
inflammation and fibrosis. Cell. 1999;96:319–28.
43. Bergstraesser LM, Srinivasan G, Jones JC, Stahl S, Weitzman SA. Expression of
hemidesmosomes and component proteins is lost by invasive breast cancer
cells. Am J Pathol. 1995;147(6):1823–39.
44. Mariotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L,
Giancotti FG. EGF-R signaling through Fyn kinase disrupts the function of
integrin alpha 6 beta 4 at hemidesmosomes: role in epithelial cell migration
and carcinoma invasion. J Cell Biol. 2001;155(3):447–57.
45. de Pereda JM, Lillo MP, Sonnenberg A. Structural basis of the interaction
between integrin alpha6beta4 and plectin at the hemidesmosomes. EMBO
J. 2009;28(8):1180–90.
46. Chioni AM, Fraser SP, Pani F, Foran P, Wilkin GP, Diss JK, Djamgoz MB. A
novel polyclonal antibody specific for the Na(v)1.5 voltage-gated Na(+)
channel ‘neonatal’ splice form. J Neurosci Methods. 2005;147(2):88–98.
47. Pal-Ghosh S, Blanco T, Tadvalkar G, Pajoohesh-Ganji A, Parthasarathy A, Zieske
JD, Stepp MA. MMP9 cleavage of the beta4 integrin ectodomain leads to
recurrent epithelial erosions in mice. J Cell Sci. 2011;124(Pt 15):2666–75.
48. Jones JL. Overdiagnosis and overtreatment of breast cancer: progression of
ductal carcinoma in situ: the pathological perspective. Breast Cancer Res.
2006;8:204.
49. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the
breast: a systematic review of incidence, treatment, and outcomes. J Natl
Cancer Inst. 2010;102(3):170–8.
50. Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares F,
Brentani HP, Carraro DM. Evidence that molecular changes in cells occur
before morphological alterations during the progression of breast ductal
carcinoma. Breast Cancer Res. 2008;10:R87.
51. Ma X-J, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression
profiling of the tumor microenvironment during breast cancer progression.
Breast Cancer Res. 2009;11:R7.
52. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW.
Normal and tumor-derived myoepithelial cells differ in their ability to
interact with luminal breast epithelial cells for polarity and basement
membrane deposition. J Cell Sci. 2002;115(1):39–50.
53. Bissell MJ, Bilder D. Polarity determination in breast tissue: desmosomal
adhesion, myoepithelial cells, and laminin 1. Breast Cancer Res. 2003;5:117–9.
54. Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue
structure and function also regulate tumor induction and progression: the
role of extracellular matrix and its degrading enzymes. Cold Spring Harb
Symp Quant Biol. 2005;70:343–56.
55. Zhang X, Hashemi SS, Yousefi M, Ni J, Wang Q, Gao L, Gong P, Gao C, Sheng J,
Mason J, et al. Aberrant c-erbB2 expression in cell clusters overlying focally
disrupted breast myoepithelial cell layers: a trigger or sign for emergence of
more aggressive cell clones? Int J Biol Sci. 2008;4(5):259–69.
56. Blackburn JS, Brinckerhoff CE. Wild-type versus mutant MMP-8 in melanoma:
‘when you come to a fork in the road, take it’. Pigment Cell Melanoma Res.
2009;22(3):248–50.
57. Moilanen M, Pirilä E, Grénman R, Sorsa T, Salo T. Expression and regulation
of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas.
J Pathol. 2002;197:72–81.
58. López-Otín C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases:
from mouse models to human cancer. Cell Cycle. 2009;8:3657–62.
59. Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has
a central role in inflammatory disorders and cancer progression. Cytokine
Growth Factor Rev. 2011;22:73–81.
Sarper et al. Breast Cancer Research  (2017) 19:33 Page 19 of 1960. Man Y-G, Sang Q-XA. The significance of focal myoepithelial cell layer
disruptions in human breast tumor invasion: a paradigm shift from the
“protease-centered” hypothesis. Exp Cell Res. 2004;301:103–18.
61. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, Allred C,
Muthuswamy SK. Deregulation of scribble promotes mammary tumorigenesis
and reveals a role for cell polarity in carcinoma. Cell. 2008;135(5):865–78.
62. Muschler J, Streuli CH. Cell-matrix interactions in mammary gland development
and breast cancer. Cold Spring Harb Perspect Biol. 2010;2(10):a003202.
63. Rabinovitz I, Toker A, Mercurio AM. Protein kinase C-dependent mobilization
of the alpha 6 beta 4 integrin from hemidesmosomes and its association
with actin-rich cell protrusions drive the chemotactic migration of
carcinoma cells. J Cell Biol. 1999;146(5):1147–60.
64. Ozawa T, Tsuruta D, Jones JC, Ishii M, Ikeda K, Harada T, Aoyama Y, Kawada A,
Kobayashi H. Dynamic relationship of focal contacts and hemidesmosome
protein complexes in live cells. J Invest Dermatol. 2010;130(6):1624–35.
65. Germain EC, Santos TM, Rabinovitz I. Phosphorylation of a novel site on the
beta 4 integrin at the trailing edge of migrating cells promotes
hemidesmosome disassembly. Mol Biol Cell. 2009;20(1):56–67.
66. Chioni AM, Grose R. FGFR1 cleavage and nuclear translocation regulates
breast cancer cell behavior. J Cell Biol. 2012;197(6):801–17.
67. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their
microenvironment. Trends Genet. 2009;25(1):30–8.
68. Astrom P, Pirila E, Lithovius R, Heikkola H, Korpi JT, Hernandez M, Sorsa T,
Salo T. Matrix metalloproteinase-8 regulates transforming growth factor-
beta1 levels in mouse tongue wounds and fibroblasts in vitro. Exp Cell Res.
2014;328(1):217–27.
69. Soria-Valles C, Gutierrez-Fernandez A, Guiu M, Mari B, Fueyo A, Gomis RR,
Lopez-Otin C. The anti-metastatic activity of collagenase-2 in breast cancer
cells is mediated by a signaling pathway involving decorin and miR-21.
Oncogene. 2014;33(23):3054–63.
70. Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Roberts T,
Pirrie S, Gaunt C, Young J, et al. Addressing overtreatment of screen
detected DCIS; the LORIS trial. Eur J Cancer. 2015;51(16):2296–303.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
